European Heart Rhythm Association (EHRA) Congress 2024 Reveals its Late-Breaking Clinical Trial Presentations for 2024

The European Heart Rhythm Association (EHRA) Congress has announced four late-breaking clinical trial sessions to be presented in April. 


EHRA 24 will take place in Berlin and online from the 7th to the 9th April 2024. Access the full programme here.


Late-Breaking Science: Clinical

Sunday 7th April, 13:45 – 14:45 Central European Time

  • Artificial intelligence-enabled single-lead ambulatory ECG can unmask conduction tissue disease – Dr Laurent Fiorina
  • Effect of targeted education of patients with atrial fibrillation on unplanned cardiovascular outcomes – Dr Hein Heidbuchel
  • Procedural and Intermediate-term Results of Electroanatomical-guided CardioNeuroablation for treatment of Atrioventricular block: PIRECNA Multicenter Study – Dr Henry Huang
  • Venous Vascular Closure System Versus Manual Compression Following Single Shot Device AF Ablation - The Style AF Study – Dr Roland Tilz
  • Impact of Atrial Fibrillation on Brain Infarcts and Cognitive Function: A Matched Cohort Analysis – Dr Michael Kuhne


Late-Breaking Science: Ablation

Monday 8th April, 13:15 – 14:15 Central European Time

  • The Safety and Effectiveness of Ultra-low Temperature Cryoablation of Monomorphic VT in Patients with Ischemic and Non-Ischemic Cardiomyopathies – Dr Atul Verma
  • First-in-Human Clinical Series of a Novel Conformable "Single-Shot" Pulsed Field Ablation Catheter for Pulmonary Vein Isolation – Dr Vivek Reddy
  • Ablation STrategies for Repeat PrOcedures in Patients with Atrial Fibrillation Recurrences despite Durable Pulmonary Vein Isolation – Dr Boris Schmidt
  • Personalized Pulmonary Vein Isolation with Very High-Power Short-Duration Lesions guided by Left Atrial Wall Thickness: the QDOT-by-LAWT Randomized Trial – TBC
  • Impact of preventive substrate catheter ablation on implantable cardioverter-defibrillator interventions in patients with ischaemic cardiomyopathy and infarct-related coronary chronic total occlusion – Dr David Zizek


Late-Breaking Science: Devices

Tuesday 9th April, 10:45 – 11:45 Central European Time

  • Clinical benefits of the Closed Loop Stimulation in Sinus Node Disease – Dr Ennio Carmine Pisano
  • Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial – Dr Julius Nikorowitsch
  • Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial – Dr William McIntyre
  • Incidence of Premature Battery Depletion and Sense-B-Noise Lead Failure in Subcutaneous Cardioverter-Defibrillator Patients: a comprehensive Analysis of a large Multicenter Registry – Dr Jonas Woermann
  • Effect of atrioventricular optimization on cardiac resynchronization response in patients with long interventricular electrical delays: A pooled analysis of the SMART-AV and SMART-CRT trials – Dr Christopher Leclercq


Late-Breaking Science Today and Tomorrow

Tuesday 9th April, 13:15 – 14:15 Central European Time

  • Conduction disturbances and arrhythmias with mitral transcatheter edge-to-edge repair versus isolated mitral surgery for mitral regurgitation: data from a nationwide analysis – TBC
  • Ground-breaking electroporation-based intervention for paroxysmal atrial fibrillation treatment: Rational and Design of the BEAT PAROX-AF randomized clinical trial – TBC
  • CAtheter-Based Ablation of atrial fibrillation compared to conventional treatment in patients with Heart Failure with Preserved Ejection Fraction – Dr Abdul Shokor Parwani
  • Initial Clinical Experience with the Volt PFA System: Acute Results of the VOLT CE Mark Feasibility Substudy – Dr Prashanthan Sanders
  • Safety, effectiveness and PVI durability of contact force-sensing dual energy focal ablation technology integrated with 3D mapping to treat paroxysmal atrial fibrillation: SmartfIRE study results - TBC